Estimated Annual Spending on Aducanumab in the US Medicare Program

This cross-sectional study examines upper bound and lower bound annualized Medicare costs for administering aducanumab to beneficiaries with the approved indications of mild cognitive impairment or mild dementia.

Detalles Bibliográficos
Autores principales: Mafi, John N., Leng, Mei, Arbanas, Julia Cave, Tseng, Chi-Hong, Damberg, Cheryl L., Sarkisian, Catherine, Landon, Bruce E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903103/
https://www.ncbi.nlm.nih.gov/pubmed/35977233
http://dx.doi.org/10.1001/jamahealthforum.2021.4495
_version_ 1784664697861046272
author Mafi, John N.
Leng, Mei
Arbanas, Julia Cave
Tseng, Chi-Hong
Damberg, Cheryl L.
Sarkisian, Catherine
Landon, Bruce E.
author_facet Mafi, John N.
Leng, Mei
Arbanas, Julia Cave
Tseng, Chi-Hong
Damberg, Cheryl L.
Sarkisian, Catherine
Landon, Bruce E.
author_sort Mafi, John N.
collection PubMed
description This cross-sectional study examines upper bound and lower bound annualized Medicare costs for administering aducanumab to beneficiaries with the approved indications of mild cognitive impairment or mild dementia.
format Online
Article
Text
id pubmed-8903103
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-89031032022-03-11 Estimated Annual Spending on Aducanumab in the US Medicare Program Mafi, John N. Leng, Mei Arbanas, Julia Cave Tseng, Chi-Hong Damberg, Cheryl L. Sarkisian, Catherine Landon, Bruce E. JAMA Health Forum Research Letter This cross-sectional study examines upper bound and lower bound annualized Medicare costs for administering aducanumab to beneficiaries with the approved indications of mild cognitive impairment or mild dementia. American Medical Association 2022-01-14 /pmc/articles/PMC8903103/ /pubmed/35977233 http://dx.doi.org/10.1001/jamahealthforum.2021.4495 Text en Copyright 2022 Mafi JN et al. JAMA Health Forum. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Research Letter
Mafi, John N.
Leng, Mei
Arbanas, Julia Cave
Tseng, Chi-Hong
Damberg, Cheryl L.
Sarkisian, Catherine
Landon, Bruce E.
Estimated Annual Spending on Aducanumab in the US Medicare Program
title Estimated Annual Spending on Aducanumab in the US Medicare Program
title_full Estimated Annual Spending on Aducanumab in the US Medicare Program
title_fullStr Estimated Annual Spending on Aducanumab in the US Medicare Program
title_full_unstemmed Estimated Annual Spending on Aducanumab in the US Medicare Program
title_short Estimated Annual Spending on Aducanumab in the US Medicare Program
title_sort estimated annual spending on aducanumab in the us medicare program
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903103/
https://www.ncbi.nlm.nih.gov/pubmed/35977233
http://dx.doi.org/10.1001/jamahealthforum.2021.4495
work_keys_str_mv AT mafijohnn estimatedannualspendingonaducanumabintheusmedicareprogram
AT lengmei estimatedannualspendingonaducanumabintheusmedicareprogram
AT arbanasjuliacave estimatedannualspendingonaducanumabintheusmedicareprogram
AT tsengchihong estimatedannualspendingonaducanumabintheusmedicareprogram
AT dambergcheryll estimatedannualspendingonaducanumabintheusmedicareprogram
AT sarkisiancatherine estimatedannualspendingonaducanumabintheusmedicareprogram
AT landonbrucee estimatedannualspendingonaducanumabintheusmedicareprogram

Ejemplares similares